Total Facility Solutions wins contract from Novartis
To install hygienic process piping at Vaccines and Diagnostics plant in Holly Springs, NC
The order is part of Novartis’ US$36m expansion of its pandemic and seasonal flu production facility, announced last December, which will create 100 new jobs at the Holly Springs development lab and pilot plant.
‘This selection to fabricate and install process piping at Novartis affirms the strength of our model for serving the life science business,’ said Joe Cestari, president of Total Facility Solutions.
‘Having invested heavily in our own North Carolina facility in 2009, we bring the infrastructure, industry expertise and experienced personnel necessary to execute on this project on time, on budget and to specification.’
The project will be operated out of Total Facility Solutions’ Raleigh, NC location, using its 4,000ft2 clean manufacturing space to complete all building work. This plant is equipped with the latest technology for orbital welding and meets stringent market requirements while facilitating just-in-time delivery to the construction site. Bovis Lend Lease and Novartis’ project managers are overseeing the project.
Total Facility Solutions (TFS) provides turnkey facilities contracting services including high-purity piping, gas and chemical systems, ultra-high purity water systems, tool and equipment installation, clean utilities, and electrical services to the semiconductor, electronics, nanotechnology, photovoltaic, life sciences, mission critical, and renewable energy industries.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Clean environments: meeting modern drug production challenges
Read moreNew medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Containment
Clean environments: meeting modern drug production challenges
New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design
Manufacturing
Symeres expands spray drying capabilities at Cranbury CMC site for poorly soluble drug candidates
The investment integrates ASD development, formulation sciences, and analytical characterisation under one roof — supporting BCS Class II and IV compounds from preclinical screening through to Phase II clinical materials
Manufacturing
Reacta Healthcare secures expanded MHRA GMP certification covering in-house analytical testing
The renewed licence strengthens the OFC material manufacturer's quality oversight across its clinical trial supply chain, reinforcing its position as the only pharmaceutical GMP-compliant oral food challenge supplier operating globally
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer